Doç. Dr. Ferit Aslan

• Brustneubildungen 6 Publikationen
  Quelle: OpenAlex / PubMed MeSHPublikationen ansehen
• Kolonneubildungen 2 Publikationen

Ausbildung

• AusbildungDicle Üniversitesi Tıp Fakültesi - Lisansmedicalpark.com.tr
• Ausbildungİzmir Katip Çelebi Üniversitesi Atatürk Eğitim ve Araştırma Hastanesi - İç Hastalıkları - Uzmanlıkmedicalpark.com.tr
• AusbildungSBÜ Ankara Dr Abdurrahman Yurtarslan Onkoloji Eğitim ve Araştırma Hastanesi - Tıbbi Onkoloji - Yandal Uzmanlıkmedicalpark.com.tr

• FachgebietMedizinische Onkologiemedicalpark.com.trAus der Quelle
• Abteilungsname in der QuelleMedikal Onkoloji (Tıbbi Onkoloji)medicalpark.com.trAus der Quelle
• EinrichtungMedical Park Ankara (Batıkent)medicalpark.com.trAus der Quelle
• ArbeitsschwerpunktBrustneubildungenAus 6 Publikationen ermittelt · Modellversion —Aus der Quelle
• Publikationen94 PublikationenOpenAlex, ORCIDAus der Quelle
• ORCID0000-0002-9153-6921ORCIDAus der Quelle
• Letzte Synchronisierung4. November 2026 20:32https://www.medicalpark.com.tr/hekimler/ferit-aslanmedicalpark.com.tr

1. Real-world effectiveness of total neoadjuvant therapy in locally advanced rectal cancer: a multicenter retrospective study

   Discover Oncology, 2026

   DOI 10.1007/s12672-026-04842-3 PMID 41870760 Frei zugänglicher VolltextQuelle: OpenAlex

2. Real-World Treatment Patterns and Survival in Uveal Melanoma: A Multicenter Cohort Study by the Turkish Oncology Group (TOG)

   Cancers, 2026

   DOI 10.3390/cancers18030394 PMID 41681877 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

3. Electrochemical detection and DNA binding mechanism of alectinib using a green-synthesized CPE/Rc-AuNP sensor supported by spectroscopic and theoretical analyses

   Surfaces and Interfaces, 2026

   DOI 10.1016/j.surfin.2026.110701 Quelle: ORCID

4. Association of Cabazitaxel Treatment Beyond 10 Cycles with Survival Outcomes in Metastatic Castration-Resistant Prostate Cancer: A Retrospective 8-Month Landmark Analysis

   Journal of Clinical Medicine, 2026

   DOI 10.3390/jcm15186966 PMID 42795739 Frei zugänglicher VolltextQuelle: ORCID

5. Clinical Characteristics and Survival Outcomes of a Clinically Defined Treatment-Emergent Neuroendocrine/Aggressive-Variant Prostate Cancer Phenotype: A Retrospective Study

   Medicina, 2026

   DOI 10.3390/medicina62091702 PMID 42796309 Frei zugänglicher VolltextQuelle: ORCID

6. Real-World Efficacy and Safety of Tyrosine Kinase Inhibitors in Patients With Advanced Bone Sarcomas: The TOGBONE Study of the Turkish Oncology Group

   JCO Global Oncology, 2026

   DOI 10.1200/go-26-00317 PMID 42715501 Frei zugänglicher VolltextQuelle: ORCID

7. Sustainable carbon electrode-based voltammetric method for sensitive determination of Alectinib, a targeted anti-cancer drug

   Diamond and Related Materials, 2026

   DOI 10.1016/j.diamond.2026.113830 Quelle: ORCID

8. Clinical Significance of Achieving No Evidence of Disease in HER2-Positive Metastatic Breast Cancer: A Multicenter Study by Turkish Oncology Group (TOG)

   Cancers, 2026

   DOI 10.3390/cancers18060915 PMID 41899520 1 Zitation (Europe PMC) Frei zugänglicher VolltextQuelle: ORCID

9. Synchronous Adrenocortical Carcinoma, Renal Cell Carcinoma, and Mediastinal Mature Teratoma with Heterozygous Variants in SMARCA4, APC, and MYBP3: A Case Report

   Journal of Oncological Sciences, 2026

   DOI 10.37047/jos.galenos.2026.2025-10-7 Frei zugänglicher VolltextQuelle: ORCID

10. Level II (IIA/IIB) Lymph Node Evaluation in Head and Neck Cancer: A Retrospective Cohort Study from a Non-Endemic Region

    Journal of Clinical Medicine, 2026

    DOI 10.3390/jcm15031068 PMID 41682748 Frei zugänglicher VolltextQuelle: ORCID